💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Dr. Lal PathLabs Limited is an India-based provider of diagnostic and related healthcare tests and services. The Company is engaged primarily in the business of running laboratories for carrying out pathological investigations in various branches of bio-chemistry, hematology,…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A high-quality, fast-growing business, fairly priced.
Dr. Lal Path Labs is scored on the pharma / healthcare framework. It keeps a healthy 17.8% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 1.25× reported profit. Free cash flow is worth about 0.7% of its market value.
Over the last 3 years revenue compounded at 12%/yr and profit at 28%/yr. Book value has grown 14%/yr. Return on equity is an elite 21.3%. In the latest quarter profit grew 29% versus the prior quarter.
At 65× earnings, the stock sits at the 55th percentile of its own 3.6-year range — the middle of where it has historically traded. Today's price already implies ~23%/yr earnings growth sustained for a decade — a demanding bar. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 56.13 | 75.62 | better |
| P/B | 12.03 | 3.49 | worse |
| EV/EBITDA | 32.88 | 19.95 | worse |
| ROE | 21.32 | — | — |
| ROCE | 26.75 | 10.81 | better |
| ROA | 17.01 | 3.84 | better |
| Quick Ratio | 3.38 | — | — |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Apollo Hospitals | 52.0 | 11.4 | 21.1% |
| Max Healthcare | 65.9 | 8.0 | 12.2% |
| Manipal Health Enterprises | 93.9 | 5.2 | 10.6% |
Revenue has grown every year across all 4 financial years shown. 12% CAGR over 3 years — steady double-digit compounder.
Net profit has risen every year — the hallmark of a compounder. Profit is growing faster than revenue (28% vs 12%) — margin expansion is at work.
Operating margin has expanded from 17% to 23% — the business is keeping more of each rupee earned.
ROE at 20% — the business earns well above its cost of equity. Capital efficiency improving — ROE up 6pp across the window.
EPS dropped in the latest year despite possible profit changes — dilution or a profit dip could be at play. Profit grew faster than EPS (28% vs 2%) — share dilution is eroding per-share value. 2% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Cash conversion at 1.2× PAT — earnings are well-backed by cash; strong accrual quality. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 14% sequentially — momentum is building. Run-rate stepping up — recent quarters average 8% above earlier ones.
Profit jumped 29% QoQ — check if this is operating leverage or a one-off item.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoter holding at 52.9% — majority control intact.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.